Metagenomi Therapeutics (MGX) EBITDA Margin (2023 - 2026)
Metagenomi Therapeutics (MGX) reported EBITDA Margin of -1867.95% for Q1 2026, down 1226.76 percentage points from -641.19% a year earlier and down 1278.15 percentage points from the prior quarter.
Metagenomi Therapeutics (MGX) EBITDA Margin (2023 - 2026) Analysis & Trends
Over the twelve months ended Mar 31, 2026, Metagenomi Therapeutics' EBITDA Margin came in at -392.04%, down 210.44 percentage points year-over-year; for FY2025, it came in at -359.76%, down 200.10 percentage points from FY2024.
- By year, EBITDA Margin came in at -159.66% in FY2024 (+6.32 pp) and -165.98% in FY2023.
- The Q1 2026 figure ranks as the lowest quarterly EBITDA Margin in data going back to Q1 2023.
- Year over year, EBITDA Margin has now declined in each of the last seven quarters, with an average year-over-year change of -276.72 percentage points over the last eight quarters.
- The high point for year-over-year EBITDA Margin in five years was Q2 2024 (a gain of 71.79 percentage points); the low point was Q1 2026 (a drop of 1226.76 percentage points).
- Per Business Quant data, the three quarters before Q1 2026 came in at -589.80% (Q4 2025), -248.47% (Q3 2025) and -230.85% (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,137.66 Bn | 1,106.24 Bn | 19.71 Bn | 53.49% |
| 2 | Johnson & Johnson | 636.13 Bn | 556.00 Bn | 17.30 Bn | 32.68% |
| 3 | AbbVie | 505.28 Bn | 478.39 Bn | 12.70 Bn | 49.01% |
| 4 | Merck | 358.10 Bn | 312.48 Bn | 12.21 Bn | 6.02% |
| 5 | Novartis Ag | 292.59 Bn | 256.58 Bn | 11.24 Bn | - |
| 6 | Astrazeneca | 265.81 Bn | 239.50 Bn | 12.86 Bn | 33.11% |
| 7 | Amgen | 237.53 Bn | 192.93 Bn | 7.24 Bn | 46.01% |
| 8 | Gilead Sciences | 194.67 Bn | 168.86 Bn | 6.22 Bn | -124.26% |
| 9 | Pfizer | 171.17 Bn | 117.82 Bn | 10.94 Bn | 39.16% |
| 10 | Metagenomi Therapeutics | 30.49 Mn | -575.25 Mn | - | - |
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -1,867.95% |
| Dec 31, 2025 | -589.80% |
| Sep 30, 2025 | -248.47% |
| Jun 30, 2025 | -230.85% |
| Mar 31, 2025 | -641.19% |
| Dec 31, 2024 | -199.31% |
| Sep 30, 2024 | -182.55% |
| Jun 30, 2024 | -77.74% |
| Mar 31, 2024 | -248.76% |
| Dec 31, 2023 | -153.20% |
| Sep 30, 2023 | -171.81% |
| Jun 30, 2023 | -149.53% |
| Mar 31, 2023 | -197.49% |
Metagenomi Therapeutics EBITDA Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda-margin&ticker=MGX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda-margin", "ticker": "MGX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebitda-margin&ticker=MGX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();